Abstract
β2 agonists and anticholinergics are two major classes of bronchodilators which form first line of drugs recommended in symptomatic treatment of asthma and COPD. Combinational therapy involving β agonists and anticholinergics prove more effective in treating airway disease than use of either agent alone. In present investigation, binding modes of Muscarinic Antagonism and β 2 Agonism (MABA) conjugates designed by Lyn et al. were revealed on structural grounds adopting molecular docking techniques. The conjugates tether β 2 motif onto M3 motif which makes it a single molecule that acts as both β 2 agonist and antimuscarinic agent. Series of conjugates were docked against β 2 adrenergic receptor and modeled M3 muscarinic acetylcholine receptor and pharmacophoric features were identified. Upon screening the conjugates on the basis of receptor ligand free energy, hydrogen bonding and internal electrostatic interaction, conjugate 11 demonstrated superior interactions with the receptors compared to remaining conjugates in the series. While, in vitro results and in silico outcomes are in agreement to reveal that conjugate 11 to possess best pharmacological profile, binding modes obtained in docking can be utilized to design new conjugates with improved biological activity. A close study of receptor residues in binding site and atoms, groups and substructures of conjugates may be used to develop favourable secondary valence forces towards receptor-ligand interactions.
Keywords: Chronic obstructive pulmonary disease (COPD), asthma, bronchodilators, muscarinic antagonism and β 2 agonism (MABA) conjugates, comparative modeling, molecular docking, pharmacophore identification.
Current Topics in Medicinal Chemistry
Title:Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates
Volume: 13 Issue: 14
Author(s): Srinivas Bandaru, M. Hema Prasad, A. Jyothy, Anuraj Nayarisseri and Mukesh Yadav
Affiliation:
Keywords: Chronic obstructive pulmonary disease (COPD), asthma, bronchodilators, muscarinic antagonism and β 2 agonism (MABA) conjugates, comparative modeling, molecular docking, pharmacophore identification.
Abstract: β2 agonists and anticholinergics are two major classes of bronchodilators which form first line of drugs recommended in symptomatic treatment of asthma and COPD. Combinational therapy involving β agonists and anticholinergics prove more effective in treating airway disease than use of either agent alone. In present investigation, binding modes of Muscarinic Antagonism and β 2 Agonism (MABA) conjugates designed by Lyn et al. were revealed on structural grounds adopting molecular docking techniques. The conjugates tether β 2 motif onto M3 motif which makes it a single molecule that acts as both β 2 agonist and antimuscarinic agent. Series of conjugates were docked against β 2 adrenergic receptor and modeled M3 muscarinic acetylcholine receptor and pharmacophoric features were identified. Upon screening the conjugates on the basis of receptor ligand free energy, hydrogen bonding and internal electrostatic interaction, conjugate 11 demonstrated superior interactions with the receptors compared to remaining conjugates in the series. While, in vitro results and in silico outcomes are in agreement to reveal that conjugate 11 to possess best pharmacological profile, binding modes obtained in docking can be utilized to design new conjugates with improved biological activity. A close study of receptor residues in binding site and atoms, groups and substructures of conjugates may be used to develop favourable secondary valence forces towards receptor-ligand interactions.
Export Options
About this article
Cite this article as:
Bandaru Srinivas, Prasad Hema M., Jyothy A., Nayarisseri Anuraj and Yadav Mukesh, Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates, Current Topics in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/15680266113139990115
DOI https://dx.doi.org/10.2174/15680266113139990115 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Focus on Pleiotropic Role of HMGB1 in the Onset of Allergic and Non- Allergic Respiratory Diseases
Current Respiratory Medicine Reviews Bronchiolitis Obliterans Following Lung Transplantation and Stem Cell Transplantation in Pediatric Patients
Current Pediatric Reviews Immunosuppression in Sepsis
Current Pharmaceutical Design Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Effect of Surfactant Chain Length on Emulsification Dynamics of Self Emulsifying Formulation of Poorly Soluble Drug
Current Drug Delivery Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Estrogen Regulation of Adipose Tissue Functions: Involvement of Estrogen Receptor Isoforms
Infectious Disorders - Drug Targets Exhaled Breath Condensate in Asthma: From Bench to Bedside
Current Medicinal Chemistry Fast Dissolving/Disintegrating Dosage Forms: Growth from Immediate Release to Sustained Release and Traditional Medicines
Recent Patents on Drug Delivery & Formulation ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Combination Therapeutic Approach for Asthma and Allergic Rhinitis
Current Clinical Pharmacology Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Interactions Between Airway Epithelial Cells and Dendritic Cells: Implications for the Regulation of Airway Inflammation
Current Drug Targets The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Current Topics in Medicinal Chemistry Real-life Experience of Clinical Efficacy of Omalizumab Use in the MiddleEast: Should We Also Be Concerned About Parasites?
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Potential Health Hazards for Cumulative Exposures to Phthalates and Ionizing Radiation in High-Risk Pediatric Population
Mini-Reviews in Medicinal Chemistry